Brisbane, Australia and Eagan, MN - Anteris Technologies Limited (ASX: AVR) advises that the early results from the first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a Surgical Aortic Valve Replacement (SAVR). The DurAVR™ valve was easy to manipulate and was able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures, promoting better results
Ann: DurAVR valve patient outcomes exceed expectations, page-2
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
0.000(0.00%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 206 | $18.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 11 | 1 |
View Market Depth
| Last trade - 08.28am 27/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable